Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: Wright Reports
Provider: GlobalData
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Nattopharma ASA Announces Results of Study on Effects of MenaQ7 on Bone Health

Tuesday, 26 Mar 2013 04:29am EDT 

Nattopharma ASA announced the publication of a new study on its MenaQ7 brand of Natural Vitamin K2 standardized to MK-7 content. The Company initiated the three-year clinical intervention study on the effects of MenaQ7 on bone health and it is available online in the journal Osteoporosis International as an Online First Article. The MenaQ7 supplementation group increased the circulating active Osteocalcin (cOC), a well-established biomarker for bone- and vitamin K status. The inactive protein, ucOC, in the MenaQ7 group, decreased with 51% +/- 21% as compared to the placebo group (+4% +/- 49%). This is pointing to the positive MenaQ7 bone effect. After three years of supplementation, improvements in both bone mineral content (BMC) and bone mineral density (BMD) were statistically significant in the MenaQ7 group. Moreover bone strength (BS) was statistically improved, demonstrating therapeutic benefits for the MenaQ7 group as compared to the placebo group. In total 244 women were included in the study and randomly assigned to either a non-treatment group receiving placebo capsules (n=124) or a treatment group receiving capsules containing 180 mcg MenaQ7 (n=120). One capsule was taken daily during a period of 36 months. Participants came to the research site every year (0, 1, 2 and 3 years) for measurements of body weight and height, blood sampling and DXA measurements. The compliance was 91.4% of the randomized participants staying in the study until its completion. 

Company Quote

-0.4 -2.25%
7:46am EDT